Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.…
Mangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X Platform
Mangoceuticals (NASDAQ: MGRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 3 employees.
The shares were at 0.1236 USD on 20 November 2026, down 94.4% over 52 weeks. Its 52-week range is 0.1207 USD to 2.410 USD: the price is 94.9% below the high and 2.4% above the low.
Its market capitalisation is 2.75M USD.
Mangoceuticals reports return on equity of -135.8% and revenue down 59.1% year over year.
Its debt exceeds its cash by 50.52K USD, a debt-to-equity ratio of 0.02. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.